ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

WSJ BLOG/Health: FDA OKs New Treatment for Soft-Tissue Sarcoma Patients

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.) By Jennifer Corbett Dooren Patients with soft-tissue sarcoma, a rare cancer that starts in the body's muscle or connective tissues, now have a new treatment option. The FDA late yesterday approved GlaxoSmithKline's drug Votrient for use in patients with soft-tissue sarcoma, Dow Jones Newswires reports. This is the first new treatment in decades for the cancer. The National Cancer Institute estimates 11,000 cases of soft tissue sarcoma are diagnosed each year in the U.S. Votrient, a tablet taken orally, is already on the U.S. market to treat advanced kidney cancer. It was approved to treat several subtypes of advanced soft-tissue sarcoma, after prior chemotherapy. Votrient's approval follows the March recommendation of an agency advisory panel that the drug's benefits outweighed its risks. Clinical data involving 369 patients showed the drug temporarily slowed tumor growth but it isn't clear if the drug prolongs lives. And the FDA notes that Votrient carries the agency's toughest warning on its label, telling patients and doctors about the potentially fatal liver damage. Patients should be monitored for liver function and treatment halt if liver function declines, the agency says. Separately Thursday, the FDA granted wider approval to Novartis's Afinitor to treat non-cancerous kidney tumors that don't require immediate surgery. Afinitor was first approved in the U.S. in 2009 to treat kidney cancer after treatment with other drugs fail. Afinitor was approved to treat kidney tumors that are caused by a rare genetic disease called tuberous sclerosis complex, or TSC, which affects about 40,000 Americans. -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com.

Stock News for Novartis (NVS)
DateTimeHeadline
03/28/201515:03:023 Top Stocks for Obamacare Lovers
03/28/201513:08:023 Little-Known Biotechs Working On Potential Blockbusters
03/28/201512:03:025 Freakishly Expensive Cancer Drugs
03/25/201509:03:02Is It Time for GlaxoSmithKline plc to Change Management?
03/24/201508:11:01Is This The Biggest Threat to Isis Pharmaceuticals Stock?
03/23/201517:44:29This Market Could Grow 6250% in 10 Years
03/23/201510:14:03This Market Could Grow 6250% in 10 Years
03/21/201512:04:06Dividend Stocks: 2 to Avoid, 1 to Buy
03/20/201507:56:19Court rejects Amgen's bid to block Neupogen biosimilar
03/20/201507:52:39How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures...
03/19/201518:46:14Judge Denies Amgen's Request to Block Novartis's Biosimilar of...
03/18/201519:18:18How The Rushed Biosimilar Law Is Yielding Go-Slow Launches
03/18/201507:45:27AstraZeneca combo lung disease drug successful in Phase 3 studies
03/17/201517:24:32ADR Shares End Mixed; BHP Billiton Shares Rise
03/17/201507:35:19New indication for Novartis bone marrow disorder drug cleared...
03/17/201504:45:54Novartis Gets EU Approval for Jakavi Rare Blood Cancer Drug
03/13/201515:51:14Oxford Biomedica Hails Novartis Contract, Narrows Loss
03/13/201506:30:41Wall Street Breakfast: Japan Marches Higher As Nikkei Breaches...
03/12/201516:33:14GSK Plans Partial Stake Sale in Aspen Pharmacare
03/12/201516:32:28GSK Plans to Sell About Half Its 12.4% Stake in Aspen Pharmacare...

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad